^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GT1708F

    i
    Other names: GT1708F, GT 1708, GT-1708
    Associations

    News

    Trials
    Company:
    Kintor Pharma
    Drug class:
    Hedgehog cell-signalling pathway inhibitor, SMO antagonist
    Related drugs:
    Associations

    News

    Trials
    over1year
    Combination of a clinical stage-hedgehog inhibitor, GT1708, improves Venetoclax-induced apoptosis by down-regulating MCL-1 proteins in AML cells (AACR 2023)
    Although HH inhibitor Glasdegib in combo with low-dose cytarabine achieved FDA approval for AML, Venetoclax (BCL-2 inhibitor/ABT-199) plus a hypomethylating agent (HMA) have been dominating the regimens in AML recently...Furthermore, ABT+Aza (Azacidine/HMA drug) induced more MCL-1 expression than ABT-199...GT1708 has been shown to reduce blast counts in three of 13 AML patients treated with higher doses and demonstrated favorite PK and safety profiles. In brief, these results support the clinical development of GT1708 in combination with ABT-199 in AML patients.
    Clinical • PARP Biomarker • IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1) • GLI1 (GLI Family Zinc Finger 1)
    |
    MCL1 overexpression • MCL1 expression • GLI1 expression
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Daurismo (glasdegib) • GT1708F